Clinical trials: COVID-19, Hydroxychloroquine Sulfate
COVID
Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19
This is a PILOT STUDY, a Phase III double-blind, randomized, placebo-controlled clinical study in which we assess the clinical effect of the prophylactic administration of hydroxychloroquine vs.
- Trial name
- Chloroquine UN (NCT04346329)
- Testing
- Hydroxychloroquine
- Where
- 2 sites in Colombia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Universidad Nacional de Colombia
COVID-19
The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial
This COVID-19 pandemic warrants urgent strategies to protect people at high risk of infection, particularly the healthcare workers.
- Trial name
- NCT04364815
- Testing
- Hydroxychloroquine plus standard preventive measures
- Where
- Philippines
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of the Philippines
COVID-19
Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients
This research is designed as an open-label,non-comparative prospective trial.
- Trial name
- NCT04458948
- Testing
- Hydroxychloroquine, Azithromycin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of New Mexico
COVID-19
Azithromycin in Hospitalized COVID-19 Patients
The present study is a randomized, double-blind, controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Shahid Modarres Medical…
- Trial name
- AIC (NCT04359316)
- Testing
- Hydroxychloroquine, Azithromycin
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
COVID
Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19
Evaluation of the efficacy and safety of hydroxychloroquine - camostat combination therapy in hospitalized patients with moderate COVID-19 infection, CLOCC-Trial Primary Objectives: The primary objective of this study is to…
- Trial name
- CLOCC (NCT04338906)
- Testing
- Camostat Mesilate, Hydroxychloroquine
- Sponsor
- Heinrich-Heine University, Duesseldorf
COVID-19
Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients
The main objective of this study is to assess the efficacy of the combination hydroxychloroquine and Azithromycin (HCQ and AZ) in reducing the infection risk among health care professionals in direct contact with COVID-19…
- Trial name
- MOPHYDA (NCT04354597)
- Testing
- HCQ & AZ
- Where
- Jordan
- Volunteers
- healthy volunteers welcome
- Sponsor
- King Hussein Cancer Center
SARS-CoV 2, COVID-19
Favipiravir vs Hydroxychloroquine vs Control in COVID -19
Hydroxychloroquine is widely used to treat autoimmune diseases. Clinical investigation has found that a high concentration of cytokines were detected in the plasma of critically ill patients infected with SARS-CoV-2, therefore…
- Trial name
- NCT04387760
- Testing
- Hydroxychloroquine, Favipiravir, Routine care for COVID-19 patients
- Where
- Bahrain
- Volunteers
- 150 people
- Sponsor
- Royal College of Surgeons in Ireland - Medical University of Bahrain
COVID-19
Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting
This is a randomized, open-label trial to assess the safety and efficacy of hydroxychloroquine, and zinc in combination with either azithromycin or doxycycline in a higher risk COVID-19 positive outpatient population.
- Trial name
- NCT04370782
- Testing
- Hydroxychloroquine, Azithromycin, Zinc Sulfate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- St. Francis Hospital, New York
Respiratory Distress Syndrome, Adult, COVID-19
Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19
Single blind randomized clinical trial designed to evaluate the efficacy of the combination of hydroxychloroquine and dexamethasone as treatment for severe Acute Respiratory Distress Syndrome (ARDS) related to coronavirus disease…
- Trial name
- DHYSCO (NCT04347980)
- Testing
- Dexamethasone and Hydroxychloroquine, Hydroxychloroquine
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Centre Chirurgical Marie Lannelongue
Covid19
Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment
This study is a randomized, double-blinded, and placebo controlled phase III clinical trial which aims to investigate the superiority of hydroxychloroquine, favipiravir or hydroxychloroquine + favipiravir treatment, initiated…
- Trial name
- NCT04981379
- Testing
- Hydroxychloroquine, Favipiravir, Favipiravir + Hydroxychloroquine
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 1,120 people
- Sponsor
- Health Institutes of Turkey
COVID-19, Respiratory Failure
Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial
Trial design: Prospective, multi-centre, randomised, pragmatic, double blind trial Methods: Participants: Adult (>18 years) within 24 hours of admission to intensive care unit with proven or suspected COVID-19 infection, whether…
- Trial name
- AZIQUINE-ICU (NCT04339816)
- Testing
- Azithromycin, Hydroxychloroquine
- Where
- Czechia
- Volunteers
- 3 people
- Sponsor
- Frantisek Duska, MD, PhD
COVID-19
Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19
Currently there are no US Food and Drug Administration (FDA)-approved drugs specifically for the treatment of patients with COVID-19.
- Trial name
- COVID-19 (NCT04344457)
- Testing
- Hydroxychloroquine, Indomethacin, Zithromax Oral Product
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Perseverance Research Center, LLC
COVID-19
Hydroxychloroquine for the Treatment of Mild COVID-19 Disease
The current outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is a global health emergency with a case fatality rate so far approximately 4% and a growing…
- Trial name
- COMIHY (NCT04340544)
- Testing
- Hydroxychloroquine
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- University Hospital Tuebingen
Coronavirus Infection, Pneumonia, Viral
Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)
Double blinded randomized clinical trial designed to evaluate the efficacy and safety of hydroxychloroquine combined with azithromycin compared to hydroxychloroquine monotherapy in patients hospitalized with confirmed COVID-19…
- Trial name
- COVIDOC (NCT04345861)
- Testing
- hydroxychloroquine + azithromycin
- Where
- France
- Volunteers
- 7 people
- Sponsor
- University Hospital, Montpellier
COVID-19, Corona Virus Infection
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
This study will assess the efficacy of hydroxychloroquine in reducing the severity of symptoms in patients with COVID-19
- Conditions
- COVID-19, Corona Virus Infection, SARS-CoV-2, 2019-nCoV
- Trial name
- NCT04334967
- Testing
- Hydroxychloroquine, Vitamin C
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Providence Health & Services
COVID-19
Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19
Hydroxychloroquine and azithromycin have been proposed as treatment of COVID-19 patients, but few reports have assessed this combination therapy in critically ill COVID-19 patients.
- Trial name
- NCT04452617
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Institut Mutualiste Montsouris
COVID-19, SARS-CoV 2
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
The purpose of this study was to evaluate the efficacy of hydroxychloroquine (HCQ) and azithromycin (Azithro) to prevent hospitalization or death in symptomatic adult outpatients with COVID-19 caused by SARS-CoV-2 infection.
- Trial name
- NCT04358068
- Testing
- Hydroxychloroquine (HCQ), Azithromycin (Azithro)
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pregnancy Related, COVID
Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum
It still unclear how SARS-CoV-2 affects pregnant women and their offspring, as well as which factors may influence obstetrical disease and outcomes, including the timing of maternal viral exposure by gestational age, the effects…
- Conditions
- Pregnancy Related, COVID, Covid-19
- Trial name
- COVID-Preg (NCT04410562)
- Testing
- Hydroxychloroquine
- Where
- 9 sites in Spain
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
Sars-CoV2
Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19
No optimal antiviral intervention has been yet validated to treat COVID-19 disease. Comorbidities, such as older age, obesity, diabetes, history of cardiovascular diseases are associated with poor prognosis.
- Trial name
- HYdILIC (NCT04372082)
- Testing
- Standard of care (SOC), Hydroxychloroquine, Association of diltiazem and niclosamide
- Sponsor
- University Hospital, Lille
SARS-CoV 2, COVID-19
Test and Treat COVID 65plus+
Patients over equal or older than 65 yearswill be treated with a hydroxychloroquine versus placebo reduced loading dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days resulting in a total…
- Trial name
- COVID65plus (NCT04351516)
- Testing
- Hydroxychloroquine
- Where
- 2 sites in Germany
- Sponsor
- University Hospital Tuebingen